Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D.
Jovanovic JV, et al. Among authors: martinelli g.
Blood. 2007 Jun 1;109(11):4635-40. doi: 10.1182/blood-2006-10-050054. Epub 2007 Feb 13.
Blood. 2007.
PMID: 17299092
Free article.